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Abstract
Increasing numbers of human immunodeficiency virus (HIV)-infected women are now accessing life-prolonging highly 
active antiretroviral therapy (HAART) in developing countries. There is a need for better understanding of interactions 
of human papillomavirus (HPV) and HIV, especially in the context of increasing life expectancy due to HAART. The data 
regarding the impact of HAART on reducing the incidence and progression and facilitating the regression of HPV 
infection and cervical abnormalities is largely inconsistent. Published studies differ in their study designs (prospective 
or retrospective cohorts or record linkage studies), screening and diagnostic protocols, duration and type of HAART 
use, recruitment and referral strategies, and definitions of screening test and disease positivity. Due to the ethical and 
resource limitations in conducting randomized trials of the impact of HAART on incidence of HPV, CIN, and cervical 
cancer among HIV-infected women, it is important to consider innovative study designs, including quasi-experimental 
trials and operations research in sentinel populations to answer the critical research questions in this area.
Background
Invasive cervical cancer (ICC), although entirely prevent-
able by early detection and treatment, remains one of the
most common malignancies among women world-
wide[1]. ICC and its precursor, cervical intraepithelial
neoplasia (CIN), are associated with persistent infection
with oncogenic 'high-risk' (HR) types of the human papil-
lomavirus (HPV). Products of HPV oncogenes E6 and E7
alter normal genetic and cellular functions and induce
malignant transformation. In women with healthy
immune systems, most HPV infections are cleared. How-
ever, for those with persistent HR-HPV infection, gradual
accumulation of altered cellular genetic material may
progress, leading to development of CIN (grades 1, 2, 3)
and eventually ICC. These changes tend to originate at
the squamocolumnar junction of the cervix and may
increasingly involve surrounding cells. Characteristic
changes in cervical cells throughout this progression can
be detected at the pre-clinical stage, allowing for treat-
ment of precursor lesions long before ICC occurs.
The developing world carries the largest burden (over
80%) of ICC, largely as a result of the expense and logisti-
cal challenges in establishing and sustaining population-
level screening and treatment programs. (Figure 1) In
many resource-limited areas, it is the most common
cause of death from malignancies in women[1]. Those
same areas also carry a large burden of human immuno-
deficiency virus (HIV) and acquired immunodeficiency
syndrome (AIDS) (Figure 2). HIV-infected women face
an increased risk for the incidence,[2,3] persistence,[4,5]
and recurrence [6,7] of HPV-induced anogenital and cer-
vical neoplastic disease[8]. Although ICC has been
labeled an AIDS-defining malignancy, there is still a lim-
ited understanding of the natural history and epidemiol-
ogy of HPV-induced neoplastic disease in HIV-infected
women.
The introduction of highly active antiretroviral therapy
(HAART*) in the late nineties resulted in dramatic
improvement of clinical outcomes and life expectancies
for people living with HIV/AIDS. It also gave hope that
improved immunological status would result in better
clearance of HPV infection in HIV-infected women,
much like other opportunistic and AIDS-associated
infections, and result in a gradual decrease in the inci-
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dence and progression of cervical neoplasia. However,
data from the industrialized world does not point to a
clear reduction in the burden and severity of cervical dis-
ease with introduction of HAART , in contrast to other
AIDS-related malignancies, most notably Kaposi's sar-
coma and non-Hodgkin lymphoma [9-12].
The need for better understanding of the interactions
between HIV and HPV in the context of HAART is there-
fore even more pressing as increasing numbers of HIV-
infected women are living longer with a persistent risk of
ICC. Guidelines for prevention and treatment strategies
for cervical cancer among HIV-infected women are
largely based on limited evidence, or in the case of
resource limited settings, are completely lacking. In this
review, we summarize the available epidemiological evi-
dence in this area, nearly all of which originates from
industrialized nations. We discuss the priorities for fur-
ther research in relation to resource-limited settings,
home to over 90% of women living with HIV/AIDS.
Methods
A systematic review of literature documenting the impact
of HAART on development of HPV-induced cervical
intraepithelial neoplasia (CIN) in HIV-infected women
was conducted using PubMed. Article selection criteria
included any clinic-based observational or population-
based linkage studies documenting both HAART status
and HPV/CIN/ICC rates. PubMed was searched with an
end date of January 2009 using Medical Subject Headings
(MeSH) "Uterine Cervical Neoplasms" OR "AlphaPapillo-
mavirus" AND "Antiretroviral Therapy, Highly Active"
limiting to English language literature. A total of 59 arti-
cles retrieved through this search were reviewed manu-
ally and additional articles were retrieved by cross
referencing. The final analysis included 22 papers that are
tabulated in Table 1. We did not include studies that were
not published as full manuscripts in peer-reviewed litera-
ture (e.g. conference abstracts or proceedings) or any
unpublished or gray literature (e.g. project reports) to
ensure inclusion of studies with completed (not interim)
analyses.
Results
The published literature on this subject is striking in lack
of standardization in study designs and methods of
screening as well as the dearth of studies among popula-
tions from resource-limited settings. The differences in
clinical versus population-based study designs, use of
prevalent versus incident lesions as endpoints, different
thresholds of diagnostic criteria for CIN, differing stan-
Figure 1 Global cervical cancer age-standardized incidence rate per 100,000 women (2002) [Source: International Agency for Research on 
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dards of lengths of follow-up evaluation periods, and
nonuniform use of diagnostic assessments by colposcopy
and/or histopathology make it difficult to draw overall
conclusions about the impact of HAART on cervical dis-
ease. We discuss these differences by stage of HPV infec-
tion/cervical disease and highlight trends and
similarities, as well as differences, in conclusions.
The definition of HAART also varies across studies,
reflecting the evolution in terminology as well as the time
horizon of adoption of newer classes of drugs over the
past decade and a half. Several authors have defined
HAART conventionally, i.e. as consisting of 2 nucleoside
reverse transcriptase inhibitors (NRTIs) + 1 protease
inhibitor (PI) or 1 non-nucleoside reverse transcriptase
inhibitor (NNRTI) [13-15]. Some referred to definitions
of HAART prevalent at their institutions, [16-19] while
others have listed multiple definitions in their
work[13,14,20,21]. Since viral suppression and immune
reconstitution appears to be dependent on the class of
drug and duration of treatment, this is an important
source of variation to be considered before drawing broad
conclusions. Furthermore, in several studies, HAART use
was measured by self-report. Some studies compared
patient groups using HAART to groups using unspecified
combinations of antiretroviral drugs [17,20,22,23] while
other studies have used antiretroviral-naïve patients in
comparison groups[14,15]. CD4+ cell count has been
uniformly used as a surrogate of immune status, with
most studies controlling for CD4+ counts in the analy-
sis[15,17,20,23,24]. Lower CD4+ cell counts have been
shown to independently predict both incidence and pro-
gression of lesions,[25] and evidence of a dose-dependent
relationship between CD4+ counts and regression of
lesions has also been documented for women on
HAART[13].
There are significant differences between studies in the
utilization of the screening/diagnostic methods for cervi-
cal pathology. Most investigators have used cytological
(Pap smear) changes with reporting based on the revised
Bethesda classification, relying on low and high-grade
squamous intraepithelial lesions (SIL) as endpoints.
However, cervical cytology has only moderate clinical
sensitivity (55%-65%) for detection of histopathologically
confirmed 'true disease status' [18], and with low inter- or
intraobserver'true correlation, even one grade of misclas-
sification can result in highly distorted outcomes on inci-
dence or regression, especially with varying thresholds of
disease positivity. Very few studies report diagnosis of
CIN by colposcopy and histopathology[20,26]. While
most investigators have measured progression of cervical
lesions independently, a prominent study has combined
persistence and progression into one comparison
group[14]. Researchers also differed in their treatment of
atypical squamous cells of undetermined significance
(ASCUS). Some considered a change of cytology result
from low grade SIL (LSIL) to ASCUS as regression, [13]
others resolved diagnoses of ASCUS with colposcopy and
histology,[27] and still others left ASCUS diagnoses out
of analysis[28].
Figure 2 Global HIV prevalence (2007) [Source: UNAIDS http://www.unaids.org].Bratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
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Table 1: Description of included studies
Author Design No. of women/cases Country HAART Definition
Heard et al 1998 Prospective Cohort 533 France 2 NRTI + 1 PI
Heard et al 2002 Prospective cohort 168 France 2 NRTIs + 1 PI or 1 
NNRTI
Heard et al 2006 Prospective cohort 289 France as defined by French 
National 
Recommendations
Orlando et al 1999 Prospective cohort 15 USA Undefined
Moore et al 2002 Prospective cohort 71 UK Undefined
Dorucci et al 2001 Prospective cohort 6 Italy NA
Lillo et al 2001 Prospective cohort 168 Italy Undefined
Del Mistro et al 2004 Prospective cohort 201 Italy 1 PI, 2 NRTIs + NNRTI; 
or 3 NRTIs
Soncini et al 2007 Prospective cohort 101 Italy 2 NRTIs + 1 PI, or 
NNRTI; or 3 NRTIs
Sirera et al 2007 Retrospective cohort 133 Spain 2 NRTIs + 1 PI or 1 
NNRTI
Sirera et al 2008 Retrospective cohort 127 Spain 2 NRTIs + 1 PI or 1 
NNRTI
Ellerbrock et al 2000 Prospective cohort 328 USA Various NRTI and 
NNRTI (1 or more in 
combination) defined 
by 1997 NIH guidelines 
or >2 PI multiple 
regimens defined
Minkoff et al 2001 Prospective cohort, 
WIHS
781 USA
Ahdieh-Grant et al 
2004
Prospective cohort, 
WIHS
312 USA
Schuman et al 2003 Prospective cohort, 
HERS
774 USA as defined by DHHS 
Guidelines
Paramsothy et al 2009 Prospective cohort, 
HERS
537 USA as defined by DHHS 
Guidelines
Intl Collaboration on 
HIV and Cancer 2000
Meta-analysis of 
prospective studies 
evaluating cancer risk 
in HIV-infected 
persons
36 USA, Europe, Australia NA
Clifford et al 2005 Prospective cohort 6 Switzerland NA
Engels et al 2006 HIV/AIDS Cancer 
Match Study
64 USA NA
Biggar et al 2007 HIV/AIDS Cancer 
Match Study
55 USA NA
Engels et al 2008 HIV/AIDS Cancer 
Match Study
28 USA NA
Dal Maso et al 2009 HIV/AIDS Cancer 
Match Study
39 Italy NABratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
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Our review covers studies that evaluate the effects of
HAART on incidence, progression, and regression of
HPV infection and CIN lesions/ICC. We only include
studies among HIV-infected women which have con-
trolled for cervical treatment to tease out the indepen-
dent effect of HAART on recurrent lesions. We present
salient features of studies grouped by impact of HAART
on HPV infection, on CIN, and on ICC, in Tables 2, 3, 4, 5
and 6.
In the sections below, we discuss the salient study find-
ings that highlight the heterogeneity in studies and the
current dearth of evidence to definitively demonstrate the
impact of HAART on HPV-associated cervical neoplastic
disease in HIV-infected women.
Studies on impact of HAART and Incidence, Prevalence and 
Clearance of HPV infection
Studies that evaluate HPV infection have been limited,
primarily because of limited availability of high quality
HPV polymerase chain reaction (PCR) typing on cervical
samples, while simultaneously evaluating the outcomes of
cytological/colposcopic abnormalities over time among
H I V - i n f e c t e d  w o m e n  s e e k i n g  HA A R T .  ( T a b l e  2 )  I n  a n
Italian cohort study of 201 HIV-infected women followed
for up to 6 years, antiretroviral therapy regimens were not
associated with increased prevalence/persistence or
regression of HPV infection[14]. Another Italian pro-
spective cohort of 168 HIV-infected women also found
no independent effect of receiving HAART with progres-
sion or regression of HPV infection, although higher and
i n c r e a s i n g  C D 4 +  T - c e l l  c o u n t s  w e r e  a s s o c i a t e d  w i t h
lower rates of HPV persistence[15]. This same study
reported, however lower incidence of HPV-16 and 18
infections in women receiving HAART compared to
women not on any treatment or women treated only with
reverse transcriptase inhibitors (RTIs)[15]. A recent anal-
ysis from the HIV Epidemiology Research Study (HERS),
a longitudinal multi-centric cohort of HIV-infected or at-
risk HIV-uninfected women in the US, has also found an
increased rate of HPV clearance among HIV-infected
women on HAART who were diagnosed with SIL[23].
( T a b l e  2 )  H A A R T  d i d  n o t  h a v e  a n  i m p a c t  o n  H I V -
infected women with normal or ASCUS Pap results.
Table 2: Summary of studies analyzing the impact of ART on HPV incidence, persistence and clearance among HIV-
infected women
Author Outcome Follow-up Results 
Comparison and 
reference 
groups
Association 
(95% CI), p value
Conclusion
Lillo et al 2001 HPV PCR 
biannually 
Outcome: 
Incidence or 
Persistence (same 
HPV genotype at 
enrollment and 
follow-up)
Median 15.4 
months
Incidence: HAART 
vs. no therapy
Persistence: 
HAART vs. no 
therapy
OR 0.28 (0.09-
0.86), p 0.02
OR 1.18, (0.37-
3.77), p 0.77
HAART protective 
against new HPV 
infections
No impact of 
HAART on 
persistence
Del Mistro et al 
2004
HPV PCR every 6-
12 months 
Outcome: 
Persistence and 
Clearance 
(undefined)
49% of N followed 
for >3 years
No odds ratios 
discussed
-- "Prevalence and 
clearance of HPV 
not associated 
with HAART"
Paramsothy et al 
2009
HPV PCR every 6 
months for 10 
visits, then 
annually 
Outcome: HPV 
Clearance (2 
negative HPV PCR 
tests at 
consecutive visits)
Median 2 years for 
women on 
HAART; 2.7 years 
not on HAART
HAART vs. no 
HAART (adjusted 
for CD4+ counts)
(i) in women with 
LSIL or HSIL
(ii) in women with 
ASCUS on 
cytology
(iii) in women 
with normal 
cytology
(i) HR 4.5 (95% CI: 
1.2 16.3)
(ii) HR 1.0 (95% CI: 
0.4-2.5)
(iii) HR 1.7 (95% CI: 
0.9-3.1)
HAART promoted 
clearance of HPV 
infection in 
women with LSIL 
or HSIL on 
cytology.
No impact of 
HAART on women 
with ASCUS 
cytology No 
impact of HAART 
on women with 
normal cytologyBratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
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In summary, the evidence about the impact of HAART
on incidence, progression and clearance of HPV infection
and lesions remains inconsistent and inconclusive. While
these cohort studies are limited by their modest sample
sizes in general, this limitation is especially significant
when establishing impact on individual HPV types or
phylogenetically similar types of HPV. It is expected that
with improved techniques, expanded availability, and
standardization of HPV primers that is being attempted
at an international level, [29], future studies will be able to
address these limitations. This will be even more impor-
tant in the era of HPV vaccination targeted at high-risk
HIV-infected women[30]. Yet, measurement of HPV
infection is always confounded by the fact that most, if
not all, detected HPV infections are transient, especially
with the constantly fluctuating immunological milieu
among HIV-infected women.
Studies evaluating the impact of HAART on incidence of 
cervical lesions
Since the goal of early detection (screening) for cervical
cancer is to target precancerous lesions, studies that mea-
sure the impact of HAART on these lesions have signifi-
cant implications for informing clinical practice as well as
public health guidelines. Results from a pre-protease
inhibitor-era cohort of HIV-infected women from the
United States did not report a protective effect of antiret-
roviral treatment on SIL, even after controlling for CD4+
status and HPV-DNA status[31]. In a well-characterized
French cohort with a median follow-up period of 28
months, there was no independent effect of receiving
a n t i r e t r o v i r a l  t h e r a p y  o r  r e s t o r e d  i m m u n e  s t a t u s  ( e v i -
denced by higher CD4+ T-cell counts) on incident SIL,
which were significantly associated only with being in the
30-39 years age group[22]. In a retrospective analysis of a
cohort from Spain of HIV -infected women with CD4+
cell counts >350 cells/mm3 and with no previous SIL,
there was no significant difference in SIL incidence
between groups receiving versus not receiving
HAART[28].
Similar findings are also reported from another Spanish
cohort that indirectly assessed the impact of HAART on
incidence of SIL as outcome on its effect on CD4+ T-cell
counts or its effect on HIV-1 viral loads[24]. The HERS
cohort results also report no decreased relative risk of
incident SIL in HIV-infected women on HAART[25].
Only one prospective cohort study, following 101 HIV-
infected women in Italy, has reported that being on
HAART reduced SIL incidence as compared to not being
on HAART, but was not able to distinguish the indepen-
dent effect of HAART versus NRTI combination antiret-
roviral therapy on SIL incidence[20].
Thus, most published literature [22,24,25,28,32] (except
one prospective cohort study [20]) suggests that being on
HAART does not reduce the incidence of cervical pre-
cancerous lesions in HIV-infected women. (Table 3)
While studies have been limited by the nature and dura-
tion of treatment regimens, there are other hypothesized
explanations for this finding. SIL/CIN represent accumu-
lative oncogenic changes in cells of the squamocolumnar
j u n c t i o n  o f  t h e  c e r v i x  c a u s e d  d u e  t o  p e r s i s t e n t  H P V
infections that may not be readily altered by the changing
nature of immunological status induced in the short term
by HAART. Additional evidence in this area will continue
Table 3: Summary of studies analyzing the impact of ART on incidence of cervical disease among HIV-infected women
Author Outcome Follow-up Results Comparison 
and reference 
groups
Association 
(95% CI), p value
Conclusion
Ellerbrock et al 2000 Histologically 
confirmed SIL 
cytology result
3-12 month period ARV therapy vs. no 
ARV therapy
RR 1.0 (0.5 - 2.0), 
p 0.94
ART has no impact on 
incidence of SIL
Schuman et al 2003 Pap result of LSIL, HSIL 4 years (median) HAART vs. no HAART RR 1.2 (0.49 - 2.94), 
p 0.7
HAART has no impact 
on incidence of SIL
Heard et al 2006 Pap change from 
normal to LSIL or HSIL
28 months (median) HAART vs. no HAART RR 0.7 (0.4 - 1.2), 
p 0.15
HAART has no impact 
on incidence of SIL
Sirera et al 2007 Pap change from 
normal to LSIL or HSIL 
in all women on 
HAART
Study period 1997 - 2005 CD4+ <200 cells/mm3 
vs. >200 cells/mm3 (All 
participants on 
HAART)
OR 0.38 (0.14 - 1.01), 
p 0.05
HAART has no impact 
on incidence of SIL
Sirera et al 2008 Pap change from 
normal to LSIL or HSIL
Study period 1997 - 2006 HAART vs. no HAART OR 1.84 (0.72 - 4.69), 
p 0.20
HAART has no impact 
on incidence of SIL
Soncini et al 2007 Histologically 
confirmed CIN
11 years HAART vs. other NRTI 
or no ARV therapy, 
adjusted for CD4+
HR 0.3 (0.13 - 0.68), p 
0.004
Only study showing 
HAART prevents 
incidence of CINBratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
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to accrue through new studies that will follow-up HIV-
infected women (many if not all without any initial pres-
ence of SIL/CIN) while comparing differences in duration
needed for development of these lesions through active
and periodic detecting incident SIL/CIN lesions.
Studies evaluating the impact of HAART on progression of 
cervical lesions
Studies evaluating the impact of HAART on progression
of preexisting SIL have reported mixed results. (Table 4)
Studies from the HERS cohort do not report an indepen-
dent impact of HAART on progression of cervical
lesions. A 2003 paper from HERS cohort reported that
being on HAART was not an independent predictor of
progression of SIL, although poorer immune status
(reflected by CD4+ cell counts <200/mm3) was associated
with significantly higher odds of progression[25]. A more
recent analysis from the same cohort found that women
on HAART with SIL were 30% less likely to progress, but
the difference was not statistically significant[23]. The
two Italian cohorts discussed above also reported no sig-
nificant difference in rates of progression between those
treated with HAART compared to those not receiving
any treatment[14,15]. However, a 2001 paper from the
other well-characterized multicentric cohort in the
United States, the Woman's Interagency Health Study
(WIHS), reported that HAART significantly decreased
cytological progression even after controlling for CD4+
count and baseline Pap result [17] in a 6-month follow-up
paired analysis (pair of consecutive visits). Cytological
progression was less likely among those with lower HIV
viral loads but was not associated with CD4+ status. Pro-
gression was more likely among those with persistent
HPV infection.
Thus, data on impact of HAART on progression from
low to higher grade SIL/CIN remains inconclusive with
conflicting study results. While it is biologically possible
that immune competence restored due to HAART may in
fact prevent the progression, it appears more likely that
progressive lesions are reflective of slow oncogenic
changes due to persistent HPV infection that are possibly
unaffected to the relatively short duration and typically
moderate immunocompetence induced due to HAART.
Comparison across studies is difficult since they differ in
how they adjust for markers of immunological status of
the patient (e.g. CD4+ counts, duration of being HIV-
infected) as well as differences in HAART (e.g. duration
of being on HAART, adherence and effectiveness of
HAART).
Table 4: Summary of studies analyzing the impact of ART on progression of cervical disease among HIV-infected women
Author Outcome Follow-up Results 
Comparison and 
reference 
groups
Association 
(95% CI), p value
Conclusion
Orlando et al 1999 Pap result lower 
to higher grade 
lesions
6 months; 114 
days (median)
CD4+ <200/mm3 
vs. CD4+ ≥ 200/
mm3 (all women 
on HAART)
OR 2.18 (95% CI 
and p-value not 
reported)
Unclear 
(incomplete 
reporting)
Schuman et al 
2003
Pap result of LSIL, 
HSIL
4 years (median) HAART vs. no ART OR 1.5 (0.90 - 
2.49), p 0.12
HAART has no 
impact on 
progression of SIL
Paramsothy et al 
2009
Pap result: Normal 
to ASCUS, ASCUS 
to LSIL, LSIL to 
HSIL
2 years for women 
on HAART, 2.7 
years not on 
HAART
HAART vs. no 
HAART
HR 0.7 (0.6 1.0), 
p >0.05
HAART has no 
impact on 
progression of SIL
Lillo et al 2001 Pap result: Normal 
to LSIL or HSIL and 
LSIL to HSIL
15.4 months 
(median)
HAART vs. no ART, 
adjusted for CD4+
OR 2.01 (0.44 - 
9.20), p 0.36
HAART has no 
impact on 
progression of SIL
Del Mistro et al 
2004
Pap result: 
"persistence or 
worsening"
49% followed for 
>3 years
HAART vs. no ART 19/36 (53%) 
women vs. 8/16 
(50%) women, 
p NR
Unclear 
(incomplete 
reporting)
Minkoff et al 2001 Pap result: Normal 
to ASCUS, ASCUS 
to LSIL, LSIL to 
HSIL
6 months: 
consecutive 
paired results on 
each participant
HAART vs. no 
HAART, adjusted 
for CD4+ and 
initial Pap result
OR 0.68 (0.52-
0.88), p NR
Only study 
showing evidence 
that HAART 
prevents 
progression of SILBratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
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Studies evaluating the impact of HAART on regression of 
cervical lesions
A 2001 report from the WIHS study concluded that
women on ART who were infected with at least 1 high-
risk HPV genotype were 40% more likely to experience
regression of SIL than those not receiving ART, after
adjustment for CD4+ cell counts and baseline cytology
status[17]. The follow-up study report from the WIHS
cohort found a regression rate of 12.5 per 100 person
years among HAART recipients (significantly associated
with lower post-HAART CD4+ counts) compared to no
regression of lesions among HIV-infected women before
HAART was introduced [13] Yet, this regression rate was
five times lower than that of HIV negative women. The
French cohort (discussed previously) reported first in
1998 and then in 2002 that women on HAART had 2-3
times the risk of regression than in women not on
HAART[27,33]. A 2004 Italian study also found that the
r a t e  o f  r e g r e s s i o n  o f  L S I L  w a s  h i g h e r  a m o n g  H A A R T
recipients[14]. However, the findings from the HERS
cohort suggests that regression of SIL is not indepen-
dently associated with HAART status. In the 2003 report,
SIL decreased by 22% for every log10 increase in HIV viral
load, but this decline was not independently related to
CD4+ counts or HAART status[25]. Also, although in the
recent HERS analysis, while HIV-infected women on
HAART were 30% more likely to exhibit regression on
their cytology results than those not on HAART, this dif-
ference did not reach statistical significance[23]. Other
studies have measured impact of surgical excisive treat-
m e n t  o n  r ecu rr e n c e  o f  HPV - m ed ia t ed  c e rvi ca l  l es i o n s,
and correlated it with HAART status[34,35]. However, it
is not possible to tease out the independent effect of
HAART in such situations and hence we have not dis-
cussed these studies in our review.
Table 5: Summary of studies analyzing the impact of ART on regression of cervical disease among HIV-infected women
Author Outcome Follow-up Results 
Comparison and 
reference 
groups
Association 
(95% CI)
Conclusion
Minkoff et al 2001 Pap result: Normal 
to ASCUS, ASCUS 
to LSIL, LSIL to 
HSIL
Variable follow-
up
HAART vs. no 
HAART, adjusted 
for CD4+ and 
initial Pap result
OR 1.4 (1.04 - 
1.82), p NR
HAART has no 
impact on 
regression of SIL
Ahdieh - Grant et 
al 2004
2 consecutive 
normal Pap 
smears after LSIL 
or HSIL
At least 7 years Regression rate in 
person years; 
HAART vs. no 
HAART
12.5% (9.9 - 
15.1%) vs. 0%, OR/
RR not reported
Unclear 
(incomplete 
reporting)
Heard et al 1998 Pap result: SIL 12 months Regression rate 
(%) in women on 
triple-drug 
HAART versus 
those not on 
HAART
35% vs. 12.5%, 
p 0.001
HAART promotes 
regression of SIL
Heard et al 2002 High grade CIN or 
HSIL and low 
grade CIN or LSIL 
or normal.
17.7 months 
(median)
HAART vs. no 
HAART, adjusted 
for CD4+
HR 1.93 (1.14 - 
3.29), p 0.01
HAART promotes 
regression of SIL
Del Mistro et al 
2004
Pap result: 
"persistence or 
worsening"
49% followed for 
>3 years
HAART vs. no ART OR 0.36 (0.08-
1.62), p NR
HAART has no 
impact on 
regression of SIL
Moore et al 2002 High grade CIN to 
lower grade CIN
10 months 
(median) 
(IQR: 8 - 14)
HAART naïve 
versus HAART - 
experienced
OR 1.9 (0.28, 
12.87), p 0.51
HAART has no 
impact on 
regression of SIL
Paramsothy et al 
2009
Pap result: Normal 
to ASCUS, ASCUS 
to LSIL, LSIL to 
HSIL
2 - 2.7 years HAART vs. no 
HAART
HR 1.3 (1.0 - 1.7), 
p >0.05
HAART has no 
impact on 
regression of SIL
Schuman et al 
2003
Pap result of LSIL, 
HSIL
4 years (median) HAART vs. no ART OR 0.86 (0.50 - 
1.47), p 0.57
HAART has no 
impact on 
regression of SILBratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
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Table 6: HAART and Incidence of Invasive Cervical Cancer
Author Outcome Design Results 
Comparison and 
reference 
groups
Association 
measures and CI
Conclusion
Intl Collaboration 
on HIV and Cancer 
2000
Cases of ICC in 
multiple 
population 
studies
Meta-analysis 1997-1999 (post-
HAART) vs. 1992-
1996 (pre-HAART)
Adj IR 2.1 vs. 1.1; 
RR 1.87 (99% CI 
0.77 - 4.56)
Higher incidence 
post HAART years, 
but not stats. 
significant
Dorucci et al 2001 Cases of ICC in 
Italian HIV 
Seroconversion 
Study
Prospective 
cohort/time-
series analysis
1996-1998 (post-
HAART) vs. 1981-
1995 (pre-HAART)
IR 4.9 vs. 1.5; RH of 
Incidence 4.25 
(0.8 - 28.24)
Higher incidence 
post HAART years, 
but not stats. 
significant
Clifford et al 2005 Cases of ICC from 
Swiss Cancer 
Registry
AIDS-Cancer 
Match Study
HAART vs. no 
HAART
SIR 0 vs. SIR 11.4; 
RR not 
estimatable
Unclear 
(incomplete 
reporting)
Engels et al 2006 Cases of ICC in 
HIV/AIDS Cancer 
Match Study
AIDS-Cancer 
Match Study
1996-2002 (post-
HAART) vs. 1990-
1995 (pre-HAART)
SIR 5.3 vs. SIR 4.2; 
RR pr year: 1.04 
(95% CI: 0.94-1.15)
Higher incidence 
post HAART years, 
but not stats. 
significant
Biggar et al 2007 Cases of ICC in 
HIV/AIDS Cancer 
Match Study
AIDS-Cancer 
Match Study
1996-2002 (post-
HART) vs. 1990-
1995 (pre-HAART)
IR 86.5 vs. 64.2; RR 
of Incidence 1.41 
(95% CI 0.81-2.46)
Higher incidence 
post HAART years, 
but not stats. 
significant
Engels et al 2008 Cases of ICC in 
HIV/AIDS Cancer 
Match Study
AIDS-Cancer 
Match Study
1996-2002 (post-
HAART) vs. 1991-
1995 (pre-HAART)
SIR 2.9 vs. 3.1; RR 
0.8 (95% CI 0.3 - 
2.0)
Lower incidence 
post HAART years, 
but not stats. 
significant
Dal Maso et al 
2009
Cases of ICC in 
Italian Cancer 
Registries
AIDS-Cancer 
Match study
1997-2004 (post-
HAART) vs. 1986-
1996 (pre-HAART)
SIR 41.5 vs. 51.0; 
RR not reported
Lower incidence 
in post HAART 
years, but 
conclusion 
unclear 
(incomplete 
reporting)
Foot note to tables: Abbreviations:
ASCUS = atypical squamous cells of undetermined significance
CD4+ = CD4+ T lymphocyte count (cells/mm3)
DHHS = U.S. Department of Health and Human Services
HAART = Highly active antiretroviral therapy
HERS = HIV Epidemiology Research Study
HIV = Human Immunodeficiency Virus
HPV = Human papillomavirus
HR = Hazard ratio
HSIL = high-grade squamous intraepithelial lesions
ICC = Invasive cervical cancer
LSIL = low-grade squamous intraepithelial lesions
NRTI = Nucleoside reverse transcriptase inhibitor
NNRTI = Non-nucleoside reverse transcriptase inhibitor
NR = Not reported
OR = Odds ratio
Pap = Papanicolaou smear
PI = Protease inhibitor
RR = Relative risk (rate ratio)
SIR = Standardized incidence ratio
WIHS = Women's Interagency HIV StudyBratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
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Thus, the evidence that HAART causes regression of
lesions is also mixed just as the evidence about HAART
on progression of lesions. In addition to the challenges in
controlling for the markers of immune suppression and
the type and nature of HAART, these cohort studies also
differ by varying definitions of clinical endpoints of SIL/
CIN, possible misclassification of results, and the small
sample sizes. Moreover, in the context of regression, the
immunological and virological interplay between HIV,
HPV, and HAART is not particularly well-understood.
The pathways by which HIV may interact with HPV are
still under investigation[36]. The HIV-1 tat gene has been
shown to enhance HPV early gene expression, which is
important in the cell transformation and the process of
SIL development [37,38]. Some studies in HIV-infected
women have also shown a decrease in vaginal Langer-
hans' cells, which promote local cervical cellular immu-
nity[39,40]. Other mucosal cytokine factors have also
been suggested as influencing local disease manifestation
in HIV/HPV coinfection[41]. There is some limited in-
vitro data to suggest that some HAART drugs, particu-
larly protease inhibitors, may have an anti-tumor effect
independent of increased immunocompetence, [42],
although this has not been proven in clinical studies.
Studies evaluating the impact of HAART on rates of 
invasive cervical cancer
In 2000, the International Collaboration on HIV and
Cancer pooled incidence estimates of ICC among all till-
date prospective cohort studies in North America,
Europe, and Australia in the pre-HAART and post-
HAART eras. The study reports no difference in ICC
incidence rates pre- or post HAART, although the pooled
cases of ICC in the study were too few (36) to make defin-
itive comparisons with the impact of HAART on other
AIDS-associated cancers such d non-Hodgkin lym-
phoma[9]. The Italianas Kaposi's Seroconversion Study
followed a prospective cohort of 483 women through pre
and post-HAART eras found increased hazards of inci-
dence of ICC in the post-HAART period but was also
limited by the small sample size[10]. AIDS-Cancer Regis-
try Matching studies have been attempted in both Europe
(Italy, Switzerland) [19,21] and in the United
States[11,12,16]. The data has revealed mixed evidence
with some suggesting higher risk in the post-HAART era
[11,16] and others the opposite[12,19]. However, none of
the reported associations in these studies are statistically
significant, given their low absolute numbers of incident
cases of invasive cervical cancer.
It has been suggested, however, that some record link-
age methodologies may have underestimated the risks of
some cancers among people withAIDS[43]. Thus, it is
difficult to interpret the significance of these findings that
suggest little change in the numbers of ICC between the
pre- and post-HAART eras. Most authors also note the
difficulty in comparing incidence of ICC across time due
to competing mortality from other causes in HIV-
infected women. Additionally, all these studies were con-
ducted in industrialized settings, where the greater access
to frequent cytological screening and early treatment ser-
vices (rather than HAART) may have actually prevented
ICC among the population of HIV-infected women.
Gaps in evidence and directions for further research
Evident in this review is that most research on the impact
of HAART on cervical cancer has been conducted and
reported from high-income nations while the developing
world unquestionably shoulders a disproportionate bur-
den of the morbidity and mortality associated with cervi-
cal cancer[1]. The same nations, especially those in
Africa, also struggle with significant burden due to HIV/
AIDS, disproportionately affecting women[44,45]. The
need for clear, evidence-based screening and treatment
guidelines is especially imperative in these settings as
hundreds of thousands of HIV-infected women are now
accessing HAART and are starting to live longer in a
moderately immunocompetent state. In these settings, a
clearer understanding of the impact of HAART on cervi-
cal cancer in HIV-infected women is necessary not only
from an academic and scientific perspective but also from
a resource allocation and program implementation point
of view. Prevention research in cervical cancer is often
within the context of clinical care. Recent efforts through
vertical HIV/AIDS care and treatment programs such as
the U.S. President's Emergency Plan for AIDS Relief
(PEPFAR) have started focusing on including cervical
cancer screening as an integral component of HIV/AIDS
care and treatment [46-48]. Newer screening methods
such as HPV testing also need to be incorporated into
more sensitive screening protocols for HIV-infected
women[49,50].
Clearly, a trial randomizing women to HAART versus
n o  H A A R T  t o  s t u d y  i m p a c t  o f  H A A R T  o n  i n c i d e n c e ,
progression or regression of HPV infection or CIN would
be unethical. Yet, opportunities for answering these ques-
tions abound. It is quite feasible to nest outcomes
research studies in HIV/AIDS care and treatment set-
tings that may allow for accumulation of data in develop-
ing evidence-based guidelines for cervical cancer
prevention in HIV-infected women. Some possible
approaches to develop this evidence in the context of
public health implementation programs and clinical, epi-
demiological, or implementation research studies could
include:
1. Nesting observational studies within pre-existing HIV-
related study cohorts
Dovetailing observational studies within pre-existing
cohorts of HIV-infected women followed-up primarilyBratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
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for other HIV/AIDS related (non-cervical cancer) out-
comes could be valuable. In many such cohort studies,
especially those in middle incomes countries, data of
varying degrees of completeness exists for cervical dis-
ease status (determined by cytology, visual inspection-
based screening, or colposcopy/histology) and HAART
status for HIV-infected women. These data can be gain-
fully exploited for evaluating associations between the
HAART and cervical neoplasia that may have context
specific significance.
2. Conducting quasi-experimental studies in HAART delivery 
settings
In settings where HAART programs are being newly
instituted, it may be possible to conduct innovative quasi-
experimental studies to answer some important research
questions. In these settings, a large proportion of HIV-
infected women have never been screened for cervical
cancer. By providing cervical cancer screening services
through cost-effective and locally appropriate methods, it
is possible to compare CIN disease status (baseline and
follow-up) of cervical screening-naïve women who are
initiating HAART newly and those who are HAART
experienced for longer periods (e.g. >6 months). This
design may provide valuable research opportunities with-
out additional investments or formal randomization pro-
cedures for HAART exposure.
3. Nesting studies within HIV-related randomized trials
Multiple studies are underway evaluating the utility of
early versus deferred initiation of HAART among HIV-
infected persons[51,52]. Such studies provide ideal exper-
imental venues for answering questions related to the
degree of impact of HAART on HPV/cervical outcomes,
especially considering that by design randomization
would control for differences in HAART status in the two
groups of women being compared.
4. Sentinel surveys
In settings with large numbers of women being treated
with HAART, sentinel surveys can be conducted by doc-
umenting cervical disease status at predetermined fre-
quencies and pre-determined sample sizes to assess
changes in CIN outcomes over time. With careful data
collection approaches and quality assurance measures,
such sentinel sites will serve as important resources for
monitoring disease trends over longer periods of time.
Conclusion
There remain significant challenges for elucidating the
impact of ART on CIN disease outcomes. As evidenced
in the review of studies above, the interactions between
HIV, HPV, HAART and the development of cervical neo-
plasia are not clearly understood. Evidence of the impact
of HAART on incidence, progression and regression of
CIN is largely mixed. Given the small absolute numbers
of invasive cervical cancer cases in HIV-infected women
in industrialized nations, the role of HAART on ICC out-
comes is difficult to determine with certainty. The rea-
sons for the wide variation in the medical literature likely
reflect complex immunological or viral-immune interac-
tions yet to be elucidated. The heterogeneity of HPV and
its ubiquity in populations, the difficulty in diagnosing
CIN, and its long natural history may also play a role.
Certainly, the biological interactions between HIV, HPV,
and HAART appear different from other cancers of viral
origins common in HIV-infected persons.
Innovative approaches are needed to elucidate the
impact of HAART in HIV-infected women in resource-
limited settings. Given that the nature of this research is
intertwined with clinical care, conduct of such epidemiol-
ogy studies dovetailed within existing public health care
and treatment programs for HIV-infected women can
have significant patient benefits as well as provide
insights to the interplay between two preventable dis-
eases: AIDS and cervical cancer.
Footnote to manuscript
* Significant differences exist while describing the drug
treatments for HIV
(antiretroviral therapy). In this article, we use the term
highly active antiretroviral therapy (HAART) broadly in
place of antiretroviral therapy (ART), although but most
published literature only uses the terminology HAART to
describe the more effective combination regimens intro-
duced after 1996 and those currently recommended by
the World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
VS conceived the manuscript idea and developed it along with LB. LB con-
ducted the data abstraction. The manuscript was drafted by both LB and VS
and both authors read and approved the final manuscript.
Acknowledgements
We thank Janeen Burlison, MSN, MPH and Carolyn Audet, PhD (both at the 
Institute for Global Health, Vanderbilt University School of Medicine in Nash-
ville, TN) for valuable comments and inputs on a previous version of this manu-
script.
Partial support for investigators was provided by NIH grants R21CA113465, 
D43TW001035, and UL1RR024975 to Vanderbilt University Medical Center.
Author Details
1Institute for Global Health, Vanderbilt University School of Medicine, Nashville, 
USA and 2Institute for Global Health and Department of Pediatrics, Vanderbilt 
University School of Medicine, Nashville, USA
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002.  CA 
Cancer J Clin 2005, 55:74-108.
2. Hawes SE, Critchlow CW, Faye Niang MA, Diouf MB, Diop A, Toure P, Aziz 
Kasse A, Dembele B, Salif Sow P, Coll-Seck AM, et al.: Increased risk of 
high-grade cervical squamous intraepithelial lesions and invasive 
Received: 29 July 2009 Accepted: 12 May 2010 
Published: 12 May 2010
This article is available from: http://www.infectagentscancer.com/content/5/1/8 © 2010 Bratcher and Sahasrabuddhe; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Infectious Agents and Cancer 2010, 5:8Bratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
http://www.infectagentscancer.com/content/5/1/8
Page 12 of 13
cervical cancer among African women with human immunodeficiency 
virus type 1 and 2 infections.  J Infect Dis 2003, 188:555-563.
3. Massad LS, Seaberg EC, Watts DH, Minkoff H, Levine AM, Henry D, Colie C, 
Darragh TM, Hessol NA: Long-term incidence of cervical cancer in 
women with human immunodeficiency virus.  Cancer 2009, 
115:524-530.
4. Adam Y, van Gelderen CJ, de Bruyn G, McIntyre JA, Turton DA, Martinson 
NA: Predictors of persistent cytologic abnormalities after treatment of 
cervical intraepithelial neoplasia in Soweto, South Africa: a cohort 
study in a HIV high prevalence population.  BMC Cancer 2008, 8:211.
5. Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR: Prevalence 
and persistence of cervical human papillomavirus infection in HIV-
positive women initiating highly active antiretroviral therapy.  J Acquir 
Immune Defic Syndr 2009, 51:274-282.
6. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, Hall C, 
Bacon M, Levine AM, Watts DH, et al.: Natural history and possible 
reactivation of human papillomavirus in human immunodeficiency 
virus-positive women.  J Natl Cancer Inst 2005, 97:577-586.
7. Gingelmaier A, Grubert T, Kaestner R, Mylonas I, Weissenbacher T, 
Bergauer F, Barthell L, Friese K: High recurrence rate of cervical dysplasia 
and persistence of HPV infection in HIV-1-infected women.  Anticancer 
Res 2007, 27:1795-1798.
8. Palefsky JM, Holly EA: Chapter 6: Immunosuppression and co-infection 
with HIV.  J Natl Cancer Inst Monogr 2003:41-46.
9. Highly active antiretroviral therapy and incidence of cancer in human 
immunodeficiency virus-infected adults.  J Natl Cancer Inst 2000, 
92:1823-1830.
10. Dorrucci M, Suligoi B, Serraino D, Tirelli U, Rezza G: Incidence of invasive 
cervical cancer in a cohort of HIV-seropositive women before and after 
the introduction of highly active antiretroviral therapy.  J Acquir 
Immune Defic Syndr 2001, 26:377-380.
11. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar 
RJ: Trends in cancer risk among people with AIDS in the United States 
1980-2002.  AIDS 2006, 20:1645-1654.
12. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, 
Hylton T, Pawlish KS, McNeel TS, Goedert JJ: Cancer risk in people 
infected with human immunodeficiency virus in the United States.  Int 
J Cancer 2008, 123:187-194.
13. Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H, 
Moxley M, Palefsky J, Sacks H, Burk RD, Gange SJ: Highly active 
antiretroviral therapy and cervical squamous intraepithelial lesions in 
human immunodeficiency virus-positive women.  J Natl Cancer Inst 
2004, 96:1070-1076.
14. Del Mistro A, Bertorelle R, Franzetti M, Cattelan A, Torrisi A, Giordani MT, 
Sposetti R, Bonoldi E, Sasset L, Bonaldi L, et al.: Antiretroviral therapy and 
the clinical evolution of human papillomavirus-associated genital 
lesions in HIV-positive women.  Clin Infect Dis 2004, 38:737-742.
15. Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S, Mastrorilli E, 
Taccagni G, Lazzarin A, Uberti-Foppa C: Human papillomavirus infection 
and associated cervical disease in human immunodeficiency virus-
infected women: effect of highly active antiretroviral therapy.  J Infect 
Dis 2001, 184:547-551.
16. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA: AIDS-related cancer and 
severity of immunosuppression in persons with AIDS.  J Natl Cancer Inst 
2007, 99:962-972.
17. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, 
Muderspach L, Burk R, Palefsky J: The effect of highly active antiretroviral 
therapy on cervical cytologic changes associated with oncogenic HPV 
among HIV-infected women.  AIDS 2001, 15:2157-2164.
18. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, 
Matchar DB: Accuracy of the Papanicolaou test in screening for and 
follow-up of cervical cytologic abnormalities: a systematic review.  Ann 
Intern Med 2000, 132:810-819.
19. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri 
T, Vercelli M, Zambon P, et al.: Pattern of cancer risk in persons with AIDS 
in Italy in the HAART era.  Br J Cancer 2009, 100:840-847.
20. Soncini E, Zoncada A, Condemi V, Antoni AD, Bocchialini E, Soregotti P: 
Reduction of the risk of cervical intraepithelial neoplasia in HIV-
infected women treated with highly active antiretroviral therapy.  Acta 
Biomed 2007, 78:36-40.
21. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti 
E, Levi F, Jundt G, Fisch T, et al.: Cancer risk in the Swiss HIV Cohort Study: 
associations with immunodeficiency, smoking, and highly active 
antiretroviral therapy.  J Natl Cancer Inst 2005, 97:425-432.
22. Heard I, Potard V, Costagliola D: Limited impact of immunosuppression 
and HAART on the incidence of cervical squamous intraepithelial 
lesions in HIV-positive women.  Antivir Ther 2006, 11:1091-1096.
23. Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, 
Rompalo AM, Cu-Uvin S, Duerr A: The effect of highly active 
antiretroviral therapy on human papillomavirus clearance and cervical 
cytology.  Obstet Gynecol 2009, 113:26-31.
24. Sirera G, Videla S, Lopez-Blazquez R, Llatjos M, Tarrats A, Castella E, Grane 
N, Alcalde C, Tural C, Rey-Joly C, Clotet B: Evolution of cervical cytologic 
changes among HIV-infected women with normal cytology in the 
HAART era.  AIDS Res Hum Retroviruses 2007, 23:965-971.
25. Schuman P, Ohmit SE, Klein RS, Duerr A, Cu-Uvin S, Jamieson DJ, 
Anderson J, Shah KV: Longitudinal study of cervical squamous 
intraepithelial lesions in human immunodeficiency virus (HIV)-
seropositive and at-risk HIV-seronegative women.  J Infect Dis 2003, 
188:128-136.
26. Moore AL, Sabin CA, Madge S, Mocroft A, Reid W, Johnson MA: Highly 
active antiretroviral therapy and cervical intraepithelial neoplasia.  
AIDS 2002, 16:927-929.
27. Heard I, Tassie JM, Kazatchkine MD, Orth G: Highly active antiretroviral 
therapy enhances regression of cervical intraepithelial neoplasia in 
HIV-seropositive women.  AIDS 2002, 16:1799-1802.
28. Sirera G, Videla S, Lopez-Blazquez R, Llatjos M, Tarrats A, Castella E, Grane 
N, Tural C, Rey-Joly C, Clotet B: Highly active antiretroviral therapy and 
incidence of cervical squamous intraepithelial lesions among HIV-
infected women with normal cytology and CD4 counts above 350 
cells/mm3.  J Antimicrob Chemother 2008, 61:191-194.
29. Ferguson M, Wilkinson DE, Zhou T: WHO meeting on the 
standardization of HPV assays and the role of the WHO HPV Laboratory 
Network in supporting vaccine introduction held on 24-25 January 
2008, Geneva, Switzerland.  Vaccine 2009, 27:337-347.
30. Palefsky J: Human papillomavirus infection in HIV-infected persons.  
Top HIV Med 2007, 15:130-133.
31. Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, Wright 
TC Jr: Incidence of cervical squamous intraepithelial lesions in HIV-
infected women.  Jama 2000, 283:1031-1037.
32. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, 
Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a 
necessary cause of invasive cervical cancer worldwide.  J Pathol 1999, 
189:12-19.
33. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD: Early 
regression of cervical lesions in HIV-seropositive women receiving 
highly active antiretroviral therapy.  AIDS 1998, 12:1459-1464.
34. Heard I, Potard V, Foulot H, Chapron C, Costagliola D, Kazatchkine MD: 
High rate of recurrence of cervical intraepithelial neoplasia after 
surgery in HIV-positive women.  J Acquir Immune Defic Syndr 2005, 
39:412-418.
35. Robinson WR, Hamilton CA, Michaels SH, Kissinger P: Effect of excisional 
therapy and highly active antiretroviral therapy on cervical 
intraepithelial neoplasia in women infected with human 
immunodeficiency virus.  Am J Obstet Gynecol 2001, 184:538-543.
36. Meys R, Gotch FM, Bunker CB: Human papillomavirus in the era of highly 
active antiretroviral therapy for human immunodeficiency virus: an 
immune reconstitution-associated disease?  Br J Dermatol 2009.
37. Vernon SD, Hart CE, Reeves WC, Icenogle JP: The HIV-1 tat protein 
enhances E2-dependent human papillomavirus 16 transcription.  Virus 
Res 1993, 27:133-145.
38. Tornesello ML, Buonaguro FM, Beth-Giraldo E, Giraldo G: Human 
immunodeficiency virus type 1 tat gene enhances human 
papillomavirus early gene expression.  Intervirology 1993, 36:57-64.
39. Spinillo A, Tenti P, Zappatore R, De Seta F, Silini E, Guaschino S: 
Langerhans' cell counts and cervical intraepithelial neoplasia in 
women with human immunodeficiency virus infection.  Gynecol Oncol 
1993, 48:210-213.
40. Olaitan A, Johnson MA, MacLean A, Poulter LW: The distribution of 
immunocompetent cells in the genital tract of HIV-positive women.  
AIDS 1996, 10:759-764.
41. Nicol AF, Nuovo GJ, Salomao-Estevez A, Grinsztejn B, Tristao A, 
Russomano F, Lapa ESJR, Oliveira MP, Pirmez C: Immune factors involved Bratcher and Sahasrabuddhe Infectious Agents and Cancer 2010, 5:8
http://www.infectagentscancer.com/content/5/1/8
Page 13 of 13
in the cervical immune response in the HIV/HPV co-infection.  J Clin 
Pathol 2008, 61:84-88.
42. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B: Antitumour effects of 
antiretroviral therapy.  Nat Rev Cancer 2004, 4:861-875.
43. Deapen D, Cockburn M, Pinder R, Lu S, Wohl AR: Population-based 
linkage of AIDS and cancer registries: importance of linkage algorithm.  
Am J Prev Med 2007, 33:134-136.
44. Lopez AD, Mathers CD: Measuring the global burden of disease and 
epidemiological transitions: 2002-2030.  Ann Trop Med Parasitol 2006, 
100:481-499.
45. Abdool Karim SS, Abdool Karim Q, Gouws E, Baxter C: Global 
epidemiology of HIV-AIDS.  Infect Dis Clin North Am 2007, 21:1-17. vii.
46. Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, Mudenda V, Hicks 
ML, Vermund SH, Stringer JS, Parham GP: Implementation of 'see-and-
treat' cervical cancer prevention services linked to HIV care in Zambia.  
AIDS 2009, 23:N1-5.
47. Pfaendler KS, Mwanahamuntu MH, Sahasrabuddhe VV, Mudenda V, 
Stringer JS, Parham GP: Management of cryotherapy-ineligible women 
in a "screen-and-treat" cervical cancer prevention program targeting 
HIV-infected women in Zambia: lessons from the field.  Gynecol Oncol 
2008, 110:402-407.
48. Mwanahamuntu MH, Sahasrabuddhe VV, Parham GP: HPV screening for 
cervical cancer in rural India.  N Engl J Med 2009, 361:305. author reply 
306.
49. Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA, Chipato 
T, Ngwalle S, Munjoma M, Shah KV: HPV-based cervical cancer screening 
in a population at high risk for HIV infection.  Int J Cancer 2000, 
85:206-210.
50. Franceschi S, Jaffe H: Cervical cancer screening of women living with 
HIV infection: a must in the era of antiretroviral therapy.  Clin Infect Dis 
2007, 45:510-513.
51. Questions and Answers: The CIPRA HT001 Clinical Trial   [http://
www3.niaid.nih.gov/news/QA/CIPRA_HT01_qa.htm]
52. HPTN 052: A Randomized Trial to Evaluate the Effectiveness of 
Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care 
Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant 
Couples   [http://www.hptn.org/research_studies/hptn052.asp]
doi: 10.1186/1750-9378-5-8
Cite this article as: Bratcher and Sahasrabuddhe, The impact of antiretrovi-
ral therapy on HPV and cervical intraepithelial neoplasia: current evidence 
and directions for future research Infectious Agents and Cancer 2010, 5:8